CAR T-cell Therapy 2025

CAR T-cell Therapy

The Central Drugs Standard Control Organisation (CDSCO) has approved Qartemi, a Chimeric Antigen Receptor (CAR) T-cell therapy, as the second "living drug" for the treatment of blood cancer.

A "living drug" involves extracting a patient's cells, modifying them, and reintroducing them back into the body for therapeutic purposes.

About CAR T-cell Therapy

CAR T-cell therapy is an advanced form of immunotherapy in which a patient's T-cells are genetically modified to target and destroy cancer cells.

T-cells are a type of white blood cell with cytotoxic properties, meaning they kill other cells. These T-cells are extracted from the patient's blood and engineered in a lab by adding a gene that codes for a man-made receptor known as CAR.

The CAR proteins enable the T-cells to recognize and bind to a specific protein found on cancer cells. The modified CAR T-cells are then reintroduced into the patient, where they specifically target and eliminate cancer cells.

Tags : UPSC 2025 current affairs preparation, UPSC current affairs January 2025, UPSC 2025 daily current affairs, Best sources for UPSC current affairs 2025, UPSC 2025 current affairs for prelims, UPSC 2025 current affairs for mains, Important current affairs for UPSC 2025, UPSC current affairs strategy 2025, UPSC 2025 current affairs notes, UPSC current affairs PDF 2025, Current affairs for UPSC 2025 preparation, UPSC 2025 current affairs online classes, UPSC current affairs quiz 2025, How to study current affairs for UPSC 2025, UPSC 2025 current affairs magazines, Current affairs for UPSC 2025 prelims and mains, Current affairs updates for UPSC 2025, UPSC 2025 current affairs analysis, Current affairs for UPSC 2025 PDF download, UPSC 2025 current affairs important topics,